Latest / Business Strategy Talks with Fexingo: Competitive Advantage, Market Positioning, and Growth Planning / How Novo Nordisk Built a Moat on GLP-1 Patents and Scale
Transcript
- Lucas: If you look at the most valuable companies in Europe right now, one name sits head and shoulders above the rest — Novo Nordisk. Market cap around six hundred billion dollars. And the engine behind almost all of that value is a single class of drugs: GLP-1 receptor agonists. Luna: Ozempic and Wegovy. Those names have basically entered the cultural lexicon at this point. Lucas: Exactly. Ozempic for diabetes, Wegovy for weight loss — both contain the same active molecule, semaglutide. And what's fascinating from a strategy standpoint is how Novo has built an almost impenetrable moat around those drugs. It's a combination of patents, yes, but also manufacturing scale and clinical data density that makes it really hard for competitors to catch up. Luna: So let's start with the patents. How strong are they, really? Lucas: The core composition of matter patent on semaglutide expires in 2026 in the US — that's this year — and has already expired in some other markets. But Novo has layered on dozens of secondary patents covering formulations, delivery devices, manufacturing processes, and methods of use. Some of those extend into the early 2030s. And in pharma, those secondary patents can be just as effective at blocking generics as the primary one. Luna: Right, because even if a generic company can make the molecule, they have to prove their version is bioequivalent, and they have to navigate all those process patents. Lucas: Precisely. And Novo has been aggressive about litigating. They've sued multiple companies — including a recent case against a Chinese manufacturer trying to enter the US market. The legal costs are a barrier in themselves. But beyond the legal strategy, there's a real operational moat here. Luna: The manufacturing piece. I've read that Novo is spending something like six billion dollars building new production capacity. Lucas: Six point eight billion, actually. Announced in 2024 and 2025 combined. They're building new facilities in Denmark, France, and the US. And here's the thing — GLP-1 drugs are peptides. They're not small molecules that can be easily synthesized in a generic pill factory. The production process is complex, involves large-scale fermentation of genetically engineered yeast, and then multiple purification steps. It's taken Novo decades to perfect that process at scale. Luna: So a competitor might have the patent, but they can't just flip a switch and start producing. Lucas: Exactly. And demand is so high right now that even with all that investment, Novo still hasn't been able to fully meet demand. There were shortages in 2023 and into '24. So anyone trying to enter the market would need to spend years and billions just to build the manufacturing capacity. And by the time they do, Novo will have moved on to the next generation. Luna: Which brings us to the pipeline. What's next after semaglutide? Lucas: They have an oral semaglutide — Rybelsus — already on the market, but the real next big thing is their once-daily oral amycretin, which is a dual GLP-1 and amylin agonist. Early data shows it may be more effective than semaglutide. And they have an even longer-acting candidate, a once-monthly injectable. So they're not just defending the current castle — they're building the next one. Luna: And this is where the clinical data moat really comes in. Novo has run massive trials — the SELECT trial alone had over seventeen thousand patients and showed cardiovascular benefits. That data becomes a barrier because regulators and payers want to see long-term safety and efficacy, which only time and huge investments can provide. Lucas: That's a key point. Even if a competitor develops a similar molecule, they would need to run their own cardiovascular outcomes trial to get the same label indications. That costs hundreds of millions of dollars and takes years. Meanwhile, Novo already has the data, the brand recognition, and the relationships with prescribers. Luna: So what could break the moat? Or at least weaken it? Lucas: The biggest near-term threat is probably oral alternatives from other companies. Eli Lilly has tirzepatide — Mounjaro and Zepbound — which is actually more effective than semaglutide in head to head trials. And Lilly has invested heavily in manufacturing too. So the competitive dynamic is shifting from 'Novo versus generic' to 'Novo versus other branded innovators.' That's a different kind of fight. Luna: And then there's the patent cliff. Even with secondary patents, eventually those expire or get invalidated. What happens then? Lucas: History suggests that once generics enter, prices drop sharply — sometimes by 80 percent or more. But Novo has time. The next few years of exclusivity are worth tens of billions in revenue. And if they can successfully transition patients to next-generation drugs before generics hit, they can maintain their premium. Luna: So the strategy is to keep moving the target. Don't let the moat become a pond. Lucas: Exactly. And that's what the best moat builders do. They don't rely on a single patent — they build a system of advantages: legal, operational, clinical. It's like a castle with multiple walls. One wall might get breached, but there's another one behind it. Luna: And speaking of castles — you know, a lot of listeners have told us they look forward to these deep dives every week. It's genuinely one of the most rewarding parts of doing this show. Lucas: Yeah, and the honest truth is, we can only keep making this many episodes because a small group of listeners chips in monthly through buy me a coffee dot com slash fexingo. No ads, no sponsors — just listener support. It's a model we really believe in. Luna: And if these conversations have moved your thinking forward in some way, that's the link. No pressure, just gratitude. Lucas: So back to Novo — the question I keep coming back to is whether the moat is sustainable over a ten-year horizon. I think the answer is yes, but it requires constant reinvestment. The moment Novo stops innovating, Lilly or someone else will eat their lunch. Luna: And there's the wildcard of oral drugs. If an oral GLP-1 from a competitor proves equally effective and more convenient, that could shift the whole landscape. Lucas: Right. But for now, Novo has one of the strongest moats in the pharmaceutical industry. It's a masterclass in how to combine IP, manufacturing, and clinical data into a defensible position. Luna: And a reminder that even the best moat needs constant maintenance. Lucas: Exactly. That's the takeaway — no moat lasts forever, but the ones that do are built on more than just a patent filing.